肝细胞癌（HCC）：超越索拉非尼-化疗
Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy.
作者信息
Kim Dae Won, Talati Chetasi, Kim Richard
机构信息
Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA.
出版信息
J Gastrointest Oncol. 2017 Apr;8(2):256-265. doi: 10.21037/jgo.2016.09.07.
Abstract
Hepatocellular carcinoma (HCC) is the most common primary liver cancer with poor prognosis. The incidence of HCC and HCC-related deaths have increased over the last several decades. However, the treatment options for advanced HCC are very limited. Sorafenib remains the only drug approved for systemic treatment for advanced HCC. However, prior to sorafenib era conventional cytotoxic chemotherapies have been studied in advanced HCC. In this review, clinical studies of systemic chemotherapy for advanced HCC will be summarized and discussed.
摘要
肝细胞癌（HCC）是最常见的原发性肝癌，预后较差。在过去几十年中，HCC的发病率和与HCC相关的死亡人数都有所增加。然而，晚期HCC的治疗选择非常有限。索拉非尼仍然是唯一被批准用于晚期HCC全身治疗的药物。然而，在索拉非尼时代之前，传统的细胞毒性化疗已在晚期HCC中进行了研究。在本综述中，将总结和讨论晚期HCC全身化疗的临床研究。
相似文献
1
Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy.肝细胞癌（HCC）：超越索拉非尼-化疗
J Gastrointest Oncol. 2017 Apr;8(2):256-265. doi: 10.21037/jgo.2016.09.07.
2
Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.不可切除肝细胞癌的治疗选择，重点是使用钇-90树脂微球的选择性内放射治疗（SIRT）
Int J Clin Pract. 2017 Nov;71(11). doi: 10.1111/ijcp.12972. Epub 2017 Jul 30.
3
Systemic therapy for hepatocellular carcinoma: beyond sorafenib.肝细胞癌的全身治疗：超越索拉非尼
Chin Clin Oncol. 2018 Oct;7(5):50. doi: 10.21037/cco.2018.10.10.
4
Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.索拉非尼不可及时代晚期肝细胞癌患者的全身细胞毒性化疗。
J Clin Gastroenterol. 2014 Mar;48(3):e22-9. doi: 10.1097/MCG.0b013e3182a54ec8.
5
Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment.晚期肝细胞癌的治疗：从免疫检查点阻断到细胞治疗潜力的免疫疗法
Transl Gastroenterol Hepatol. 2018 Nov 7;3:89. doi: 10.21037/tgh.2018.10.16. eCollection 2018.
6
Systemic therapies in hepatocellular carcinoma.肝细胞癌的全身治疗
Dig Dis. 2009;27(2):175-88. doi: 10.1159/000218351. Epub 2009 Jun 22.
7
Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature.索拉非尼联合方案作为晚期肝细胞癌一线治疗的系统评价文献复习。
Crit Rev Oncol Hematol. 2014 Jul;91(1):1-8. doi: 10.1016/j.critrevonc.2013.12.013. Epub 2014 Jan 7.
8
Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.钇-90微球放射性栓塞术与索拉非尼治疗晚期肝细胞癌的比较（SARAH）：一项随机对照试验的研究方案
Trials. 2014 Dec 3;15:474. doi: 10.1186/1745-6215-15-474.
9
Locoregional and systemic therapy for hepatocellular carcinoma.肝细胞癌的局部区域和全身治疗
J Gastrointest Oncol. 2017 Apr;8(2):215-228. doi: 10.21037/jgo.2017.03.13.
10
A narrative review of systemic treatment options for hepatocellular carcinoma: state of the art review.肝细胞癌全身治疗选择的叙述性综述：最新进展综述
J Gastrointest Oncol. 2022 Feb;13(1):426-437. doi: 10.21037/jgo-21-274.
引用本文的文献
1
Predictors of recurrence after conversion therapy in unresectable hepatocellular carcinoma treated with HAIC, bevacizumab, and sintilimab.经肝动脉灌注化疗（HAIC）、贝伐单抗和信迪利单抗治疗的不可切除肝细胞癌转化治疗后复发的预测因素。
Front Immunol. 2025 Aug 26;16:1644570. doi: 10.3389/fimmu.2025.1644570. eCollection 2025.
2
Tissue Factor Pathway Inhibitor 2 Enhances Hepatocellular Carcinoma Chemosensitivity by Activating CCAR2-GADD45A-Mediated DNA Damage Repair.组织因子途径抑制因子2通过激活CCAR2-GADD45A介导的DNA损伤修复增强肝细胞癌的化疗敏感性。
Int J Biol Sci. 2025 Jul 11;21(10):4629-4646. doi: 10.7150/ijbs.111142. eCollection 2025.
3
Exploring Autophagy-Related Gene Expression in Hepatocellular Carcinoma via TCGA, GEPIA2, and HPA Databases: Implications for Prognosis.通过TCGA、GEPIA2和HPA数据库探索肝细胞癌中自噬相关基因的表达：对预后的影响
J Hepatocell Carcinoma. 2025 Jul 22;12:1557-1586. doi: 10.2147/JHC.S520917. eCollection 2025.
4
A diaryl urea derivative, SMCl inhibits cell proliferation through the RAS/RAF/MEK/ERK pathway in hepatocellular carcinoma.一种二芳基脲衍生物SMCl通过RAS/RAF/MEK/ERK途径抑制肝癌细胞增殖。
Front Pharmacol. 2025 Jul 10;16:1605515. doi: 10.3389/fphar.2025.1605515. eCollection 2025.
5
Therapeutic Glypican-3 CRISPR Genome-Editing Using UltraLarge Porous Silica Nano-Depot for the Treatment of Hepatocellular Carcinoma.使用超大孔隙二氧化硅纳米储存库进行治疗性磷脂酰肌醇蛋白聚糖-3基因编辑以治疗肝细胞癌
Small Sci. 2024 Nov 21;5(4):2400447. doi: 10.1002/smsc.202400447. eCollection 2025 Apr.
6
Clinical Profile and Outcome of Patients With Advanced Hepatocellular Carcinoma (HCC) Taking Sorafenib or Lenvatinib: Real-World Experience From a Low-Middle Resource Country.服用索拉非尼或乐伐替尼的晚期肝细胞癌（HCC）患者的临床特征与预后：来自一个中低收入国家的真实世界经验
Cureus. 2025 May 7;17(5):e83681. doi: 10.7759/cureus.83681. eCollection 2025 May.
7
Anoikis in hepatocellular carcinoma: genetic alterations and immune microenvironment insights from single-cell and computational analysis.肝细胞癌中的失巢凋亡：来自单细胞和计算分析的基因改变与免疫微环境见解
Discov Oncol. 2025 May 31;16(1):969. doi: 10.1007/s12672-025-02770-2.
8
Revealing the prognostic potential of natural killer cell-related genes in hepatocellular carcinoma: the key role of NRAS.揭示自然杀伤细胞相关基因在肝细胞癌中的预后潜力：NRAS的关键作用
Discov Oncol. 2025 May 18;16(1):807. doi: 10.1007/s12672-025-02200-3.
9
cPDS Promotes Cell Apoptosis by Reducing the Translational Efficiency of BIRC3 mRNA in HCC.cPDS通过降低肝癌中BIRC3 mRNA的翻译效率促进细胞凋亡。
Dig Dis Sci. 2025 Apr 16. doi: 10.1007/s10620-025-08916-0.
10
IL35 modulates HBV-related HCC progression via IL6-STAT3 signaling.白细胞介素35通过白细胞介素6-信号转导子和转录激活子3信号通路调节乙型肝炎病毒相关的肝癌进展。
Sci Rep. 2025 Feb 21;15(1):6293. doi: 10.1038/s41598-025-89015-y.
本文引用的文献
1
Cancer statistics, 2016.癌症统计数据，2016 年。
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
2
Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12.抗癌细胞因子：干扰素-α2、白细胞介素（IL）-2、IL-15、IL-21和IL-12的生物学特性及临床效应
Semin Oncol. 2015 Aug;42(4):539-48. doi: 10.1053/j.seminoncol.2015.05.015. Epub 2015 Jun 3.
3
Prognosis of untreated hepatocellular carcinoma.未治疗的肝细胞癌的预后。
Hepatology. 2015 Jan;61(1):184-90. doi: 10.1002/hep.27443. Epub 2014 Nov 26.
4
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.全球癌症发病与死亡：GLOBOCAN 2012 数据源、方法与主要模式。
Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.
5
Role of estrogen in hepatocellular carcinoma: is inflammation the key?雌激素在肝细胞癌中的作用：炎症是关键吗？
J Transl Med. 2014 Apr 8;12:93. doi: 10.1186/1479-5876-12-93.
6
The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis.肝脏中的 EGFR 信号系统：从肝保护到肝癌发生。
J Gastroenterol. 2014 Jan;49(1):9-23. doi: 10.1007/s00535-013-0907-x. Epub 2013 Dec 10.
7
Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study.节拍卡培他滨治疗晚期肝细胞癌患者的Ⅱ期临床研究。
Oncologist. 2013;18(12):1256-7. doi: 10.1634/theoncologist.2013-0093. Epub 2013 Nov 13.
8
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.亚洲晚期肝细胞癌患者奥沙利铂联合氟尿嘧啶/亚叶酸与多柔比星姑息化疗的随机、多中心、开放标签研究。
J Clin Oncol. 2013 Oct 1;31(28):3501-8. doi: 10.1200/JCO.2012.44.5643. Epub 2013 Aug 26.
9
Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma.索拉非尼对比卡培他滨治疗晚期肝细胞癌。
Med Oncol. 2013;30(3):655. doi: 10.1007/s12032-013-0655-z. Epub 2013 Jul 4.
10
Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma.改良的顺铂/干扰素 α-2b/多柔比星/5-氟尿嘧啶（PIAF）化疗在无肝炎或肝硬化的患者中与提高初始不可切除肝癌的反应率、可切除性和生存率相关。
Cancer. 2013 Sep 15;119(18):3334-42. doi: 10.1002/cncr.28209. Epub 2013 Jul 2.
Zotero 插件